Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 297 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo cream Clear all
Completed Phase 2 Interventional

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

NCT00869336
View directory record Official record
Conditions
Tinea Pedis
Interventions
Luliconazole Cream 1% - 2 wks, Placebo Comparator -2 wks, Luliconazole Cream 1% - 4 wks, Placebo Comparator - 4 wks
Drug
Lead sponsor
Tinea Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Fridley, Minnesota • Portland, Oregon • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Is Topical CBD Effective in Treating Thumb Joint Arthritis

NCT04611347
View directory record Official record
Conditions
CBD, Hand Osteoarthritis
Interventions
CBD, Shea Butter
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

NCT00585247
View directory record Official record
Conditions
Port Wine Stain
Interventions
Imiquimod, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

NCT05763082
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
roflumilast cream 0.3%, Zoryve, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)

NCT00609323
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
lidocaine and tetracaine cream 7%/7%, Placebo
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Lexington, Kentucky • High Point, North Carolina • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

NCT03826628
View directory record Official record
Conditions
Facial Angiofibroma, Tuberous Sclerosis
Interventions
rapamycin, placebo
Drug
Lead sponsor
Dermatology Specialties Limited Partnership
Industry
Eligibility
6 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

NCT04921969
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 1, 2026, 3:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Warmth, Anticipation, Sensation, Aversion, and Body-part Imaging Study

NCT04653064
View directory record Official record
Conditions
Pain
Interventions
Placebo Cream, Control Cream
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

Dendritic Cell Vaccine for Patients With Brain Tumors

NCT01204684
View directory record Official record
Conditions
Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
Interventions
autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

Acute Otitis Media (AOM) Therapy Trial in Young Children

NCT00377260
View directory record Official record
Conditions
Acute Otitis Media
Interventions
amoxicillin-clavulanate, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 23 Months
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

"Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."

NCT00533468
View directory record Official record
Conditions
Pain
Interventions
Lidocaine Cream 4%, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
0 Days to 60 Days
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

NCT05119920
View directory record Official record
Conditions
Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
19
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Topical Estriol for Vaginal Health

NCT00908570
View directory record Official record
Conditions
Vaginal Health
Interventions
estriol, Placebo
Drug
Lead sponsor
Gynuity Health Projects
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2011 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

NCT01235728
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412
View directory record Official record
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 1 Interventional

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

NCT06733402
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pain Control for Laser Epilation in Pilonidal Disease

NCT06640946
View directory record Official record
Conditions
Pilonidal Disease
Interventions
Topical lidocaine, Sham cream
Drug
Lead sponsor
David Mooney
Other
Eligibility
16 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 3 Interventional

Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury

NCT00765700
View directory record Official record
Conditions
Sprain, Strain, Acute Soft Tissue Injury
Interventions
Topical Ketoprofen 10% Cream, Topical Placebo Cream
Drug
Lead sponsor
Imprimis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 1, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

NCT04811131
View directory record Official record
Conditions
Vitiligo
Interventions
ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment, NB-UVB phototherapy sham treatment
Drug · Device
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Rolling Meadows, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

NCT03431610
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
SB414 2%, SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED

NCT02390960
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil Cream, Placebo Cream, Penile Plethysmography (RigiScan)
Drug · Device
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
San Diego, California • New Orleans, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 1, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01815450
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100, BLI1100 - modified formulation, Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
15
States / cities
Fremont, California • Jacksonville, Florida • Ormond Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 1, 2026, 3:32 PM EDT